International Review of Ophthalmology ›› 2021, Vol. 45 ›› Issue (5): 386-392.doi: 10.3760/cma.j.issn.1673-5803.2021.05.004

Previous Articles     Next Articles

Research progress on conjunctival melanoma

Wang Jinjin,  Li Jing,  Ma Jianmin   

  1. Department of Ophthalmology,  Beijing Tongren Eye Center,  Beijing Tongren Hospital,  Capital Medical University; Beijing  Key Laboratory of Ophthalmology and Visual Science,  Beijing 100730,  China
  • Received:2021-02-02 Online:2021-10-22 Published:2021-10-25
  • Contact: Ma Jianmin, Email: jmma@sina.com
  • Supported by:
    Beijing Hospital Management Center "Climbing peak" Project Special Fund Support (DFL20190201); Beijing Natural Science Foundation (7182038); Natural Science Foundation of China Project (81800864) 

Abstract: Conjunctival melanoma (CM) is a rare tumor with a mortality rate of 30%. This kind of tumor shows the worst prognosis among conjunctival malignant tumors. CM is caused by the malignant transformation of melanocytes in the basal layer of conjunctival epithelium. In some patients,  the corresponding conjunctival pigmented lesions before conjunctival melanoma,  such as primary pigmented melanosis and conjunctival pigmented nevus can be found. It is most common in the bulbar conjunctiva or corneoscleral margin,  but also in the palpebral conjunctiva. CM can invade the eyeball or orbit,  and metastasize to local lymph nodes,  brain and other organs. Histopathological examination is the gold standard for diagnosis. Most CM can be resected with surgery. Postoperative adjuvant therapy can reduce the risk of local recurrence and distant metastasis.(Int Rev Ophthalmol, 2020, 45: 386-392)

Key words: conjunctival melanoma/diagnosis, conjunctival melanoma/treatment ,